Evidence map›Paper›PMID 27144537›Full record

ArticleRadiology2016

Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model.

Volker Neuschmelting, Hannah Lockau, Vasilis Ntziachristos, Jan Grimm, Moritz F Kircher

Open access · greenAbstract read
In one paragraph

Article in Radiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Multiplexed imaging in oncology.Nature biomedical engineering · 2022
    Review
  7. Review
  8. Article
  9. Label-Free Visualization of Early Cancer Hepatic Micrometastasis and Intraoperative Image-Guided Surgery by Photoacoustic Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  10. Review
  11. Perfluorocarbons-BasedInternational journal of nanomedicine · 2020
    Review
  12. Article
  13. Article
  14. Optoacoustic mesoscopy for biomedicine.Nature biomedical engineering · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Nanotheranostics · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Volker NeuschmeltingFrom the Department of Radiology (V. Neuschmelting, H.L., J.G., M.F.K.), Molecular Pharmacology Program (H.L., J.G.), and Center for Molecular Imaging and Nanotechnology (CMINT) (J.G., M.F.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute for Biological and Medical Imaging, Helmholtz Zentrum, Munich, Germany (V. Ntziachristos); Department of Biological Imaging, Technische Universität München, Munich, Germany (V. Ntziachristos); and Departments of Radiology (J.G., M.F.K.) and Pharmacology (J.G.), Weill Cornell Medical College, New York, NY.
Hannah LockauFrom the Department of Radiology (V. Neuschmelting, H.L., J.G., M.F.K.), Molecular Pharmacology Program (H.L., J.G.), and Center for Molecular Imaging and Nanotechnology (CMINT) (J.G., M.F.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute for Biological and Medical Imaging, Helmholtz Zentrum, Munich, Germany (V. Ntziachristos); Department of Biological Imaging, Technische Universität München, Munich, Germany (V. Ntziachristos); and Departments of Radiology (J.G., M.F.K.) and Pharmacology (J.G.), Weill Cornell Medical College, New York, NY.
Vasilis NtziachristosFrom the Department of Radiology (V. Neuschmelting, H.L., J.G., M.F.K.), Molecular Pharmacology Program (H.L., J.G.), and Center for Molecular Imaging and Nanotechnology (CMINT) (J.G., M.F.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute for Biological and Medical Imaging, Helmholtz Zentrum, Munich, Germany (V. Ntziachristos); Department of Biological Imaging, Technische Universität München, Munich, Germany (V. Ntziachristos); and Departments of Radiology (J.G., M.F.K.) and Pharmacology (J.G.), Weill Cornell Medical College, New York, NY.
Jan GrimmFrom the Department of Radiology (V. Neuschmelting, H.L., J.G., M.F.K.), Molecular Pharmacology Program (H.L., J.G.), and Center for Molecular Imaging and Nanotechnology (CMINT) (J.G., M.F.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute for Biological and Medical Imaging, Helmholtz Zentrum, Munich, Germany (V. Ntziachristos); Department of Biological Imaging, Technische Universität München, Munich, Germany (V. Ntziachristos); and Departments of Radiology (J.G., M.F.K.) and Pharmacology (J.G.), Weill Cornell Medical College, New York, NY.
Moritz F KircherFrom the Department of Radiology (V. Neuschmelting, H.L., J.G., M.F.K.), Molecular Pharmacology Program (H.L., J.G.), and Center for Molecular Imaging and Nanotechnology (CMINT) (J.G., M.F.K.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Institute for Biological and Medical Imaging, Helmholtz Zentrum, Munich, Germany (V. Ntziachristos); Department of Biological Imaging, Technische Universität München, Munich, Germany (V. Ntziachristos); and Departments of Radiology (J.G., M.F.K.) and Pharmacology (J.G.), Weill Cornell Medical College, New York, NY.
Memorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cerenkov luminescence imaging for image-guided cancer surgeryR01CA183953 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GRIMM, JAN · 2015 to 2019
$2.6M
Cerenkov-emission based nanosensors to detect biologic activities in vivoR01EB014944 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI GRIMM, JAN · 2012 to 2015
$1.6M
MRI-Photoacoustic-Raman Nanostars for Pre- and Intraoperative Multimodal ImagingR01EB017748 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI KIRCHER, MORITZ FLORIAN · 2014 to 2017
$1.6M
Interactions of Stress and NicotineK08DA016396 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN, JOSHUA A · 2005 to 2009
$866k
Combined Pre & Intraoperative Brain Tumor Imaging Strategy using a Dual-ModalityK08CA163961 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KIRCHER, MORITZ FLORIAN · 2012 to 2016
$845k
NCI NIH HHS K08 CA163961NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA183953NIBIB NIH HHS R01 EB014944NIBIB NIH HHS R01 EB017748NIDA NIH HHS K08 DA016396
6 · The paper itself

Abstract

Purpose To study whether multispectral optoacoustic tomography (MSOT) can serve as a label-free imaging modality for the detection of lymph node micrometastases and in-transit metastases from melanoma on the basis of the intrinsic contrast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). Materials and Methods The study was approved by the institutional animal care and use committee. Sequential MSOT was performed in a mouse B16F10 melanoma limb lymph node metastasis model (n = 13) to survey the development of macro-, micro- and in-transit metastases (metastases that are in transit from the primary tumor site to the local nodal basin) in vivo. The in vitro limit of detection was assessed in a B16F10 cell phantom. Signal specificity was determined on the basis of a simultaneous lymphadenitis (n = 4) and 4T1 breast cancer lymph metastasis (n = 2) model. MSOT was compared with intravenous FDG PET/CT. The diagnosis was assessed with histologic examination. Differences in the signal ratio (metastatic node to contralateral limb) between the two modalities were determined with the two-tailed paired t test. Results The mean signal ratios acquired with MSOT in micrometastases (2.5 ± 0.3, n = 6) and in-transit metastases (8.3 ± 5.8, n = 4) were higher than those obtained with FDG PET/CT (1.1 ± 0.5 [P < .01] and 1.3 ± 0.6 [P < .05], respectively). MSOT was able to help differentiate even small melanoma lymph node metastases from the other lymphadenopathies (P < .05 for both) in vivo, whereas FDG PET/CT could not (P > .1 for both). In vitro, the limit of detection was at an approximate cell density of five cells per microliter (P < .01). Conclusion MSOT enabled detection of melanoma lymph node micrometastases and in-transit metastases undetectable with FDG PET/CT and helped differentiate melanoma metastasis from other lymphadenopathies. (©) RSNA, 2016 Online supplemental material is available for this article.

Indexed as

AnimalsDiagnostic ImagingDisease Models, AnimalLymphatic MetastasisLymph NodesMelanomaMiceNeoplasm MicrometastasisPhotoacoustic TechniquesSensitivity and Specificity

Identifiers

PMID27144537
PMCPMC4942996
OpenAlexW2346162764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.